Pharmacokinetics and Pharmacodynamics Study of RPC1063 in RMS

A Phase I, Multicenter, Randomized, 12-Week, Open-Label Study to Evaluate the Multiple Dose Pharmacokinetics and Pharmacodynamics of RPC 1063 in Patients With Relapsing Multiple Sclerosis

The purpose of this study is to learn about the pharmacokinetics and pharmacodynamics of RPC1063 in RMS.

The purpose of this study is to characterize the full pharmacokinetic and pharmacodynamics profiles of RPC1063 in patients with relapsing multiple sclerosis (RMS) following multiple-dose administration of the two different dosing regimens that are being evaluated in the Phase 3 RMS studies.

Key Inclusion Criteria:

• MS, as diagnosed by the revised 2010 McDonald criteria
• Exhibits a relapsing clinical course consistent with RMS and history of brain MRI lesions consistent with MS
• Expanded disability status scale (EDSS) score between 0 and 6.0

Key Exclusion Criteria:

• Primary progressive MS
• Clinically relevant cardiovascular conditions or other relevant diseases that could impact the implementation or interpretation of the trial, or put the patient at risk